PT 141 neusspray is a nasal form of bremelanotide. Learn how PT-141 nasal spray dosing, onset, side effects, and FDA status compare with the injection.
PT 141 neusspray is bremelanotide delivered through the nose instead of under the skin. "Neusspray" is simply the Dutch word for nasal spray, so most people searching that term are looking for the same product sold in the US as pt-141 nasal spray. The important catch is that bremelanotide is not FDA-approved as a nasal spray in the United States.
Below is what the research actually shows about the intranasal form, how it compares with the approved injection, and which safety issues matter most.
What PT 141 Neusspray Is and Where It Came From
Bremelanotide is a synthetic peptide that activates melanocortin receptors, which are involved in appetite, pigmentation, and sexual desire. It was originally studied as a tanning agent, and researchers noticed a side effect that changed the drug's direction: participants reported increased sexual interest.
Early human trials delivered the drug intranasally, so much of what is known about the nasal route comes from those studies. The developer eventually switched to a subcutaneous injection because absorption through the nasal lining was inconsistent and required far larger doses.
The FDA approved that injectable version, sold as Vyleesi, in 2019. It is the only FDA-approved bremelanotide product in the United States.
PT-141 works differently from PDE5 inhibitors like sildenafil. Those drugs increase blood flow to the genitals, while bremelanotide acts on the central nervous system and is thought to influence desire rather than circulation.
PT-141 Nasal Spray vs the Approved Injection
The table below compares the routes that appear most often in research papers and product listings.
| Form | Typical reported dose | Onset | Duration | FDA status |
|---|---|---|---|---|
| Subcutaneous injection (Vyleesi) | 1.75 mg | About 45 minutes | Roughly 2–4 hours | Approved for premenopausal women with HSDD |
| Intranasal (research setting) | 7.5–20 mg | 30–60 minutes | Roughly 2–4 hours | Not approved |
| Compounded or vendor nasal spray | Varies by seller | Variable | Variable | Not approved and not quality-reviewed |
The gap in dosing is the key takeaway. Nasal absorption is poor, so intranasal studies used milligram amounts roughly ten times larger than the injected dose.
PT-141 Dosage: Why the Nasal Numbers Look So High
Published intranasal trials tested 7.5 mg, 10 mg, and 20 mg doses. There is no standard, FDA-reviewed pt-141 dosage chart for nasal spray, and compounded products differ in concentration from one batch to the next.
A spray labeled "10 mg" by one vendor may deliver substantially more or less drug than the same label from another seller. Without third-party testing, there is no way to confirm potency.
Response also varies between individuals. Some men who use it describe a narrower effective window than the clinical data in women, and higher doses tend to bring more nausea rather than more benefit.
How Long Does PT-141 Last?
In nasal studies, effects generally started within 30 to 60 minutes and faded within a few hours. That makes how long does pt-141 last a fairly easy question: most reports describe a window of roughly two to four hours, with side effects peaking in the first hour.
The injectable form behaves on a similar timeline. Individual response still varies widely, and some people notice nothing at all from a dose that affects someone else strongly.
Side Effects and Safety Concerns
The most common side effects in bremelanotide trials were nausea, flushing, headache, and vomiting. Nausea was dose-related and was the main reason participants in intranasal studies stopped treatment.
- A temporary rise in blood pressure that can last several hours after a dose
- Focal hyperpigmentation, meaning dark patches on the skin, gums, or breasts, with repeated use
- Nasal burning, irritation, or congestion from spray formulations
- Injection site reactions with the approved injectable product
Bremelanotide is not recommended for people with uncontrolled high blood pressure or known cardiovascular disease. It should not be used during pregnancy or while breastfeeding.
Anyone considering bremelanotide should talk with a healthcare professional first, particularly if they take blood pressure medication or have a heart condition.
Sourcing, Compounding, and Quality Risks
Because no nasal bremelanotide product is approved, there is no regulated supply chain behind it. Sprays sold online are typically compounded by a pharmacy, imported from overseas, or labeled "for research use only," which means they are not intended for human consumption.
Forum guides explaining how to make pt-141 nasal spray from lyophilized powder carry real risks: incorrect concentration, bacterial contamination, and no way to verify sterility or potency.
Independent testing of research peptides has repeatedly found that the contents do not match the label, and some samples contain no active peptide at all.
Bottom Line
PT 141 neusspray is an unapproved intranasal form of bremelanotide that was studied in early trials at much higher milligram doses than the approved injection. It has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality.
Vyleesi, a 1.75 mg subcutaneous injection, remains the only FDA-approved bremelanotide product, and it is approved only for premenopausal women with hypoactive sexual desire disorder. People with high blood pressure, heart disease, or pregnancy should avoid bremelanotide entirely.
Frequently Asked Questions
Is PT-141 nasal spray FDA-approved?
No. The FDA has not approved any nasal bremelanotide product for human use. The only approved version is Vyleesi, a 1.75 mg subcutaneous injection indicated for premenopausal women with hypoactive sexual desire disorder. Nasal sprays sold online are compounded, imported, or marketed as research chemicals.
What PT-141 nasal spray dosage is used in research?
Early intranasal trials tested doses of 7.5 mg, 10 mg, and 20 mg. Those amounts are much larger than the 1.75 mg injection because absorption through the nasal lining is limited. There is no standard nasal dose, and compounded products vary in concentration.
How long does PT-141 nasal spray take to work?
Reports and trial data suggest effects usually begin within 30 to 60 minutes and last roughly two to four hours. Side effects such as nausea and flushing tend to peak early, within the first hour after dosing. Individual response varies from person to person.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.